glp 1 유사체 GLP-1 유사체의 유용성과 이점 및 안전성에 대한 고찰 Part Ⅲ] 비만 치료제 문제는

Ongoing collaboration among research institutions has further supported the exchange of scientific knowledge related to peptide applications

Interested in Glutathione

Afamelanotide : MC1R preference

Conservative approach (better tolerated) Slower escalation: Week 1-6: 0.6mg weekly Week 7-12: 1.2mg weekly Week 13-18: 1.8mg weekly Week 19+: 2.4mg weekly (or stay at 1.8mg) Benefits: Fewer side effects Better tolerability Good for GI-sensitive people Still effective (slightly less weight loss) Maintenance at lower dose: Some maintain at 1.8mg or 2.0mg 8-10% weight loss still achievable Better long-term sustainability More affordable Aggressive protocol (maximum weight loss) Higher doses (some trials): Week 1-4: 0.6mg weekly Week 5-8: 1.2mg weekly Week 9-12: 2.4mg weekly (faster) Week 13-16: 3.0mg weekly Week 17+: 4.5mg weekly (maximum) Warning: Higher side effect risk Nausea very common at 4.5mg Not necessary for most people Only if excellent tolerability Research setting primarily Expected additional benefit: 4.5mg: ~11-12% vs 2.4mg: ~10% Modest additional loss May not justify side effects Individualized decision Combination with semaglutide dosing CagriSema protocol: Start both simultaneously OR add cagrilintide to existing semaglutide Semaglutide: Titrate to 2.4mg over 16-20 weeks Cagrilintide: Titrate to 2.4mg over 12-16 weeks Both weekly injections (can be same day) Sequential approach (if already on semaglutide): Stable on semaglutide 2.4mg for 4+ weeks Add cagrilintide starting 0.6mg weekly Titrate cagrilintide to 2.4mg over 12 weeks Continue both Expected results: 15-25% body weight loss Superior to either alone Well-documented synergy See our cagrilintide and semaglutide , semaglutide dosage calculator , and tirzepatide dosing guide guides

doi:10.1016/j.jmb.2009.03.026

Back Couzin-Frankel, J (14 Dec 2023) 'Obesity meets its match', Science